LONDON/NEW YORK (Financial Times) -- A key European Medicines Agency panel has signaled it is unlikely to grant approval to Biogen's drug for Alzheimer's disease, adding to the debate surrounding a controversial treatment that retails at $56,000 a year.
On Wednesday, Biogen said Aduhelm, the drug it has developed with Japan's Eisai, received a "negative trend vote" from the Committee for Medicinal Products for Human Use panel on its application for marketing authorization in the bloc. The panel is expected to give its formal decision next month, Biogen said.
